Physician profile
Jesse D Jensen
NPI 1619294337
$5,203.03
in general payments reported to CMS, 2019-2025
29 companies · $736 in 2025
The $736 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $331 · 2021: $717 · 2022: $792 · 2023: $1,200 · 2024: $1,149 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $580.03 | 2023-2025 | Zoryve |
| Abbvie INC. | $579.09 | 2019-2025 | |
| Ucb, INC. | $577.21 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $422.29 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $388.95 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $329.81 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $295.93 | 2023-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $285.88 | 2020-2024 | Taltz, Olumiant, Ebglyss |
| Merz North America, INC. | $256.13 | 2022-2023 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $250.51 | 2019-2024 | Jublia, Cabtreo |
| Genzyme Corporation | $200.16 | 2021-2025 | |
| Galderma Laboratories, L.P. | $194.11 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $193.16 | 2019-2020 | |
| Leo Pharma INC. | $155.23 | 2021-2024 | Adbry |
| Dermavant Sciences, INC. | $70.62 | 2023 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $62.74 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $58.30 | 2021-2024 | Opzelura |
| Organon LLC | $50.84 | 2025 | Vtama |
| Amgen INC. | $46.83 | 2022-2025 | Otezla |
| Dermira, INC. | $34.68 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $33.01 | 2024 | Tremfya |
| Vyne Pharmaceuticals INC. | $27.44 | 2021 | |
| Almirall LLC | $27.32 | 2025 | Seysara |
| Journey Medical Corporation | $25.44 | 2025 | |
| Seqirus USA INC | $20.00 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.26 | 2022 | |
| Apyx Medical Corporation | $9.41 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.